Borrelia burgdorferi Infections is an indication for drug development with over 20 pipeline drugs currently active. According to GlobalData, preregistered drugs for Borrelia burgdorferi Infections have a 100% likelihood of approval (LoA) indication benchmark. GlobalData’s report assesses how phase transition success rate (PTSR) and likelihood of approval (LoA) scores for pipeline drugs in Borrelia burgdorferi Infections compared to historical benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Borrelia burgdorferi Infections overview

Borrelia burgdorferi infections are a type of tick-borne disease that can cause various symptoms depending on the stage of infection. The bacteria are transmitted to humans by the bite of infected blacklegged ticks, which are found mainly in wooded or grassy areas. The infection can be diagnosed by blood tests and treated with antibiotics. If left untreated, the infection can lead to complications such as arthritis, neurological problems or heart problems. The prevention of Borrelia burgdorferi infections involves avoiding tick bites by wearing protective clothing, using insect repellents and checking for ticks after spending time outdoors. The removal of ticks as soon as possible can also reduce the risk of infection. There is no vaccine available for this disease.

For a complete picture of PTSR and LoA scores for drugs in Borrelia burgdorferi Infections, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article. 

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.